The impact of serum thyroid-stimulation hormone levels on the outcome of hepatitis B virus related acute-on-chronic liver failure: an observational study.
Hepatitis B virus
Liver failure
Prognosis
Thyroid-stimulation hormone
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
07 Jul 2022
07 Jul 2022
Historique:
received:
23
05
2021
accepted:
29
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Thyroid dysfunction has been reported in severe liver diseases. The aim of this study was to analyze the impact of serum thyroid-stimulation hormone (TSH) levels on the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). This retrospective cohort study included 1,862 patients with HBV-related ACLF. Risk factors associated with 30-day and 90-day survival, hazard ratios (HRs), and 95% confidence intervals (CIs) for TSH were estimated using Cox proportional hazards regression. The Area Under the ROC curve (AUROC) analysis was carried out, and the cut-off values were calculated. After grouping by the cut-off value, survival was compared between the groups using the log-rank test. This study data is from the "Survival Cohort Study (SCS)", which has been registered at ClinicalTrials.gov (NCT03992898). Multivariate analysis indicated that an elevated TSH level was a highly significant predictor for 30-day survival (HR = 0.743, 95% CI: 0.629-0.878, P < 0.001) and 90-day survival (HR = 0.807, 95% CI: 0.717-0.909, P < 0.001). The AUROC of TSH level for 30-day and 90-day mortality were 0.655 and 0.620, respectively, with the same best cut-off values of 0.261 µIU/mL. Log-rank test showed that the group with higher TSH level had higher 30-day (78.5%, 95% CI: 76.1%-80.9% vs. 56.9%, 95% CI: 53.4%-60.4%; P < 0.001) and 90-day survival rate (61.5%, 95% CI: 58.6%-64.4% vs. 42.8%, 95% CI: 39.3%-46.3%; P < 0.001). Similar findings were observed in subgroups analysis. After adjusting for age and other risk factors, the higher level of TSH remained associated with 30-day survival (HR = 0.602, 95% CI: 0.502-0.721, P < 0.001) and 90-day survival (HR = 0.704, 95% CI, 0.609-0.814, P < 0.001). Serum TSH level significantly correlate with HBV-related ACLF patients' survival and may be of value for predicting 30-day and 90-day survival of patients with HBV-related ACLF.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid dysfunction has been reported in severe liver diseases. The aim of this study was to analyze the impact of serum thyroid-stimulation hormone (TSH) levels on the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF).
METHODS
METHODS
This retrospective cohort study included 1,862 patients with HBV-related ACLF. Risk factors associated with 30-day and 90-day survival, hazard ratios (HRs), and 95% confidence intervals (CIs) for TSH were estimated using Cox proportional hazards regression. The Area Under the ROC curve (AUROC) analysis was carried out, and the cut-off values were calculated. After grouping by the cut-off value, survival was compared between the groups using the log-rank test. This study data is from the "Survival Cohort Study (SCS)", which has been registered at ClinicalTrials.gov (NCT03992898).
RESULTS
RESULTS
Multivariate analysis indicated that an elevated TSH level was a highly significant predictor for 30-day survival (HR = 0.743, 95% CI: 0.629-0.878, P < 0.001) and 90-day survival (HR = 0.807, 95% CI: 0.717-0.909, P < 0.001). The AUROC of TSH level for 30-day and 90-day mortality were 0.655 and 0.620, respectively, with the same best cut-off values of 0.261 µIU/mL. Log-rank test showed that the group with higher TSH level had higher 30-day (78.5%, 95% CI: 76.1%-80.9% vs. 56.9%, 95% CI: 53.4%-60.4%; P < 0.001) and 90-day survival rate (61.5%, 95% CI: 58.6%-64.4% vs. 42.8%, 95% CI: 39.3%-46.3%; P < 0.001). Similar findings were observed in subgroups analysis. After adjusting for age and other risk factors, the higher level of TSH remained associated with 30-day survival (HR = 0.602, 95% CI: 0.502-0.721, P < 0.001) and 90-day survival (HR = 0.704, 95% CI, 0.609-0.814, P < 0.001).
CONCLUSIONS
CONCLUSIONS
Serum TSH level significantly correlate with HBV-related ACLF patients' survival and may be of value for predicting 30-day and 90-day survival of patients with HBV-related ACLF.
Identifiants
pubmed: 35799116
doi: 10.1186/s12876-022-02406-7
pii: 10.1186/s12876-022-02406-7
pmc: PMC9260984
doi:
Substances chimiques
Hormones
0
Thyrotropin
9002-71-5
Banques de données
ClinicalTrials.gov
['NCT03992898']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Subventions
Organisme : National Major Science and Technology Projects of China
ID : 2018ZX10302204
Organisme : National Major Science and Technology Projects of China
ID : 2017ZX10203201003
Organisme : National Natural Science Foundation of China
ID : 81901940
Organisme : National Natural Science Foundation of China
ID : 82070612
Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2015 Aug 25;5:13409
pubmed: 26302721
Dig Liver Dis. 2012 Feb;44(2):166-71
pubmed: 21978580
Hepatol Int. 2019 Jul;13(4):353-390
pubmed: 31172417
Endocrinology. 2001 Feb;142(2):812-22
pubmed: 11159854
Cell. 2003 Oct 17;115(2):151-62
pubmed: 14567913
Hepatology. 2014 Jun;59(6):2309-20
pubmed: 24122933
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
J Hepatol. 2015 Apr;62(4):831-40
pubmed: 25463539
Endocrine. 2009 Oct;36(2):198-204
pubmed: 19543840
Ann Hepatol. 2015 Mar-Apr;14(2):218-24
pubmed: 25671831
J Lipid Res. 2015 May;56(5):963-71
pubmed: 25713102
Am J Med Sci. 2012 Sep;344(3):175-9
pubmed: 22143128
Oxid Med Cell Longev. 2020 Jan 06;2020:1249630
pubmed: 31998431
Oncotarget. 2017 Jun 29;8(40):67821-67828
pubmed: 28978075
J Endocrinol. 2010 Apr;205(1):1-13
pubmed: 20016054
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Neuroimmunomodulation. 2022;29(1):77-84
pubmed: 34392245
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
J Dig Dis. 2013 Sep;14(9):484-90
pubmed: 23692973
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4636-42
pubmed: 19187127
Clin Endocrinol (Oxf). 2008 Mar;68(3):481-4
pubmed: 17941901
Arq Gastroenterol. 2015 Apr-Jun;52(2):124-8
pubmed: 26039830
J Gastroenterol Hepatol. 2013 Mar;28(3):513-21
pubmed: 23215950
Aliment Pharmacol Ther. 2018 Oct;48(7):750-760
pubmed: 30069888
Front Med (Lausanne). 2021 Jun 16;8:692669
pubmed: 34222294
Med Sci Monit. 2016 Apr 08;22:1171-9
pubmed: 27056188
Biomed Pharmacother. 2007 Sep;61(8):463-7
pubmed: 17570630
Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):607-10
pubmed: 19719920
Hepatol Int. 2009 Dec;3(4):571-81
pubmed: 19680733
QJM. 2002 Sep;95(9):559-69
pubmed: 12205333
Circulation. 2003 Feb 11;107(5):708-13
pubmed: 12578873
Gut. 2018 Dec;67(12):2181-2191
pubmed: 28928275
Expert Rev Neurother. 2015 Mar;15(3):315-26
pubmed: 25673072